JSON
Magnusson JM, Larsson H, Alsaleh A, Ekelund J, Karason K, Schult A, Friman V, Felldin M, Søfteland JM, Dellgren G, Oltean M
Transpl Int - (-) - [2021-10-28; online 2021-10-28]
Although it is known that solid organ transplant recipients fare worse after COVID-19 infection, data on the impact of COVID-19 on clinical outcomes and allograft function in lung transplant (LTx) recipients are limited and based mainly on reports with short follow-up. In this nationwide study, all LTx recipients with COVID-19 diagnosed from February 1st, 2020 to April 30th, 2021, were included. The patients were followed until August 1st 2021, or death. We analysed demographics, clinical features, therapeutic management, and outcomes, including lung function. Forty-seven patients were identified: median age was 59 (10-78) years, 53.1% were male, and median follow-up was 194 (23-509) days. COVID-19 was asymptomatic or mild at presentation in 48.9%. Nine patients (19.1%) were vaccinated pre-COVID infection. Two patients (4.3%) died within 28 days of testing positive, and the overall survival rate was 85.1%. The patients with asymptomatic or mild symptoms had a higher median % expected forced expiratory volume during the first second than the patients with worse symptoms (p=0.004). LTx recipients develop the entire spectrum of COVID-19, and in addition to previously acknowledged risk factors, lower pre-COVID lung function was associated with more severe disease presentation.
PubMed 34709680
DOI 10.1111/tri.14148
Crossref 10.1111/tri.14148